Chicago to Host Heart Disease Conference in November
The American Heart Association Scientific Sessions 2026 will present new research on transthyretin amyloid cardiomyopathy.
Updated on Oct. 26, 2026 in Heart Disease
Live Poll
Do you trust that new medical research discoveries will lead to better care for your health?
The American Heart Association Scientific Sessions 2026 will take place in Chicago from November 6-9, 2026. This gathering will feature significant clinical trial data and research regarding transthyretin amyloid cardiomyopathy.
Why it matters
The conference aims to update medical professionals on advancements in the detection and treatment of ATTR-CM. These findings are expected to refine clinical characterization and management strategies for the disease.
The conference highlights 2-year open-label extension data and includes findings from 10 specialty centers currently participating in the IMPACT ATTR initiative. Researchers will also present results from phase 3 clinical trials.
The players
American Heart Association
The American Heart Association is a non-profit organization that funds cardiovascular medical research and educates consumers on healthy living.
The details
Program highlights include presentations on the phase 3 HELIOS-B trial of vutrisiran, the CARDIO-TTRansform trial of eplontersen, and the REVEAL study of iodine-124 evuzamitide. Additionally, experts will discuss the use of multimodal AI systems for diagnosis and CRISPR-Cas9 gene editing for disease stabilization.
Timeline
The American Heart Association Scientific Sessions 2026 will occur November 6-9, 2026.
Health Landscape
The event builds upon the foundation established by the AHA IMPACT ATTR initiative to improve standard care practices. This marks a significant progression in moving specialized amyloidosis research into broader clinical application.
These developments may eventually lead to earlier identification of undiagnosed ATTR-CM through new AI-based diagnostic systems. Patients should monitor future clinical guidance to see how these emerging therapies might influence local treatment options.
The takeaway
The upcoming sessions highlight a pivot toward gene-editing and AI-driven diagnostics in managing complex cardiac conditions. Patients and families affected by amyloidosis should consult with their cardiologists about how these research developments might shape future care plans.
Further reading
Learn more about the latest research and clinical standards at the Heart Disease section.
Source note: This article includes information reported by Medscape.
Live Poll
Do you trust that new medical research discoveries will lead to better care for your health?
